נגישות
menu      
חיפוש מתקדם
תחביר
חפש...
הספר "אוצר וולקני"
אודות
תנאי שימוש
ניהול
קהילה:
אסיף מאגר המחקר החקלאי
פותח על ידי קלירמאש פתרונות בע"מ -
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract
Year:
2014
Source of publication :
World Journal of Gastroenterology
Authors :
פינס, מרק
;
.
Volume :
20
Co-Authors:
Pines, M., Institute of Animal Sciences, Volcani Center, PO Box 6, Bet Dagan, Israel
Facilitators :
From page:
14778
To page:
14786
(
Total pages:
9
)
Abstract:
Organ fibrosis and architectural remodeling can severely disrupt tissue function, often with fatal consequences. Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli, and the key cellular mediator of fibrosis comprises the myofibroblasts which, when activated, serve as the primary collagen-producing cells. Complex links exist between fibrosis, regeneration and carcinogenesis, and the concept that all organs contain common tissue fibrosis pathways that could be potential therapeutic targets is an attractive one. Because of the major impact of fibrosis on human health there is an unmet need for safe and effective therapies that directly target fibrosis. Halofuginone inhibits tissue fibrosis and regeneration, and thereby affects the development of tumors in various tissues along the gastrointestinal tract. The high efficacy of halofuginone in reducing the fibrosis that affects tumor growth and tissue regeneration is probably due to its dual role in inhibiting the signaling pathway of transforming growth factor β, on the one hand, and inhibiting the development of Th17 cells, on the other hand. At present halofuginone is being evaluated in a clinical trial for other fibrotic indication, and any clinical success in that trial would allow the use of halofuginone, also for all other fibrotic indications, including those of the gastrointestinal tract. © 2014 Baishideng Publishing Group Inc. All rights reserved.
Note:
Related Files :
Cancer
cystic fibrosis
digestive system cancer
Fibrosis
Review
stellate cell
עוד תגיות
תוכן קשור
More details
DOI :
10.3748/wjg.v20.i40.14778
Article number:
Affiliations:
Database:
סקופוס
Publication Type:
סקירה
;
.
Language:
אנגלית
Editors' remarks:
ID:
20913
Last updated date:
02/03/2022 17:27
Creation date:
16/04/2018 23:40
You may also be interested in
Scientific Publication
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract
20
Pines, M., Institute of Animal Sciences, Volcani Center, PO Box 6, Bet Dagan, Israel
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract
Organ fibrosis and architectural remodeling can severely disrupt tissue function, often with fatal consequences. Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli, and the key cellular mediator of fibrosis comprises the myofibroblasts which, when activated, serve as the primary collagen-producing cells. Complex links exist between fibrosis, regeneration and carcinogenesis, and the concept that all organs contain common tissue fibrosis pathways that could be potential therapeutic targets is an attractive one. Because of the major impact of fibrosis on human health there is an unmet need for safe and effective therapies that directly target fibrosis. Halofuginone inhibits tissue fibrosis and regeneration, and thereby affects the development of tumors in various tissues along the gastrointestinal tract. The high efficacy of halofuginone in reducing the fibrosis that affects tumor growth and tissue regeneration is probably due to its dual role in inhibiting the signaling pathway of transforming growth factor β, on the one hand, and inhibiting the development of Th17 cells, on the other hand. At present halofuginone is being evaluated in a clinical trial for other fibrotic indication, and any clinical success in that trial would allow the use of halofuginone, also for all other fibrotic indications, including those of the gastrointestinal tract. © 2014 Baishideng Publishing Group Inc. All rights reserved.
Scientific Publication
You may also be interested in